Bio-Rad Laboratories Class B

BIO.B

Overview Fund Activity

1 day

5 days

1 month

3 months

6 months

Year to date

1 year

5 years

10 years

About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Employees: 7,700

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more capital invested

Capital invested by funds: $518K [Q1] → $520K (+$2.04K) [Q2]

0% more funds holding

Funds holding: 5 [Q1] → 5 (+0) [Q2]

0% more ownership

Funds ownership: 0.04% [Q1] → 0.04% (+0%) [Q2]

See Fund Rankings

Financial journalist opinion

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth for 2025, indicating that it encounters problems in expanding its operations. The four relative valuations conducted in this article reported mixed results. These results suggest that the company trades at fair value.

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady clinical diagnostics products sales growth.

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.

See News Rankings

Charts implemented using Lightweight Charts™